

Turning the tide of the mental health crisis

With next-generation treatments through telehealth

We need better tools to fight the mental health crisis

- 1 in 4 adults suffered from a mental illness in the past year
- Less than 50% of adults with mental illness receive treatment due to lack of providers, cost, and stigma
- Current treatments provide **poor outcomes** due to limited efficacy and serious side effects

Mindbloom is increasing access and improving outcomes

Treating depression and anxiety through telehealth with ketamine-assisted therapy

- Licensed clinicians see patients through telehealth
- At-home treatments with remote patient monitoring, coaching, and therapeutic content
- Telehealth increases availability and lowers cost
 - Available in 37 states, serving 86% of the U.S. population
 - In-office treatment with esketamine (Spravato) costs 13-20X more than Mindbloom with equivalent effectiveness

Largest clinical study of ketamine therapy demonstrates efficacy and safety

Real-world evidence from **1,247 Mindbloom patients**

Efficacy and Safety:

- 89%** reported improvements in symptoms of anxiety and/or depression
- 30%** achieved remission (virtually no symptoms)
- 62%** of patients who reported suicidal ideation at baseline no longer reported any suicidal ideation
- 4.7%** reported side effects (vs. 38% for SSRI antidepressants¹)




Published in the *Journal of Affective Disorders*

References

[Source 1](#) | [Source 2](#) | [Source 3](#)
[Source 4](#) | [Source 5](#)

Percent of Patients with >50% Reduction of Depression Symptoms



Visit mindbloom.com or contact michael@mindbloom.com for more information.

World-Class Medical Advisors



Dr. Benjamin Weinstein
Chair of Psychiatry at Houston Methodist Hospital



Dr. Adam Gazzaley
Professor of Neurology, Physiology, & Neuroscience at UCSF



Dr. Teddy Akiki
Researcher at Stanford University's Dept. of Psychiatry and Behavioral Studies

And other psychiatrists and researchers from Houston Methodist, MAPS, and other leading institutions

Meet them all [here](#).

Ketamine therapy is an evidence-based treatment

Ketamine was approved by the FDA in 1970 as an anesthetic/analgesic

- Esketamine (Spravato), a ketamine derivative, was approved by the FDA in 2019 for treatment-resistant depression

Listed as an essential medicine by WHO since 1985


Over 100 studies and a 20-year track record of success for mood disorders

Testimonials: Meet Melody

A **mom**, **veteran**, and **nurse** who came to Mindbloom for her depression and anxiety

Mindbloom treatment provided:

- Relief from 35 years of symptoms
- Quieting of negative inner dialogue
- Sense of purpose, self-love, and hope



View Melody's full story [here](#), and see more client stories [here](#)